selinexor,tafasitamab,lenalidomide
morphosys,karyopharm,incyte
['tafasitamab', 'selinexor', 'dlbcl', 'lymphoma']
clinical discussion on dlbcl #lymphoma treatment selection criteria must consider logistic factors as approval for referrals, manufacturing slot availability, care coordination and patient factors. at - session at #ash2022 
Lymphoma Coalition | Head of Membership & Alliiances. 
Patient Advocate interested in R&D, Capacity Building, Patient's rights, Policy. Cooperation is my motto.